Splinter T A, Carney D N, Teeling M, Peake M D, Kho G S, Oosterom R, Cooper E H
University Hospital Dijkzigt, Department of Oncology, Rotterdam, The Netherlands.
J Cancer Res Clin Oncol. 1989;115(4):400-1. doi: 10.1007/BF00400971.
Serum samples were collected from 115 small-cell lung cancer patients before each course of chemotherapy and during follow-up. Levels of neuron-specific enolase (NSE) were measured and compared to the clinical assessments of the course of the disease, which were done by the responsible physician without knowledge of NSE-values. The predictive accuracy of an increase or decrease of NSE for a major response (CR + PR), SD or PD was 98%. Importantly no false-positive rises of NSE were observed. On the basis of this large number of data it seems justified to conclude that in common clinical practice the treatment of small-cell lung cancer patients can be monitored by serial measurements of NSE alone.
在化疗的每个疗程之前以及随访期间，从115例小细胞肺癌患者身上采集血清样本。检测神经元特异性烯醇化酶（NSE）水平，并与疾病进程的临床评估结果进行比较，该临床评估由负责医生在不了解NSE值的情况下进行。NSE升高或降低对主要缓解（CR + PR）、疾病稳定（SD）或疾病进展（PD）的预测准确率为98%。重要的是，未观察到NSE出现假阳性升高。基于大量数据，似乎有理由得出结论：在普通临床实践中，仅通过连续检测NSE就可以监测小细胞肺癌患者的治疗情况。
